IP Library Granted Patent US 9,587,223
Granted Patent B2
US 9,587,223 · App. 14/010,578 · Granted Mar 7, 2017

Protocols for making hepatocytes from embryonic stem cells

Inventors: Ramkumar Mandalam (Union City, CA); Saadia Faouzi (Daly City, CA); Isabelle Nadeau (San Francisco, CA); Kristina Pfendler-Bonham (South San Francisco, CA); Namitha Rao (San Jose, CA); Melissa K. Carpenter (London, CA); Lakshmi Rambhatla (Redwood City, CA); Choy-Pik Chiu (Cupertino, CA)
Assignee: Asterias Biotherapeutics, Inc.
C12N5/067C12N2500/30C12N2500/36C12N2500/62C12N2501/11C12N2501/115C12N2501/119C12N2501/12C12N2501/13C12N2501/148C12N2501/155C12N2501/23C12N2501/33C12N2501/335C12N2501/385C12N2501/39C12N2502/13C12N2503/02C12N2506/02C12N2533/90C12N2533/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,587,223
App. No.
14/010,578
Granted
Mar 7, 2017
Kind
B2
Abstract

This disclosure provides a newly developed strategy and particular options for differentiating pluripotent stem cells into cells of the hepatocyte lineage. Many of the protocols are based on a strategy in which the cells are first differentiated into early germ layer cells, then into hepatocyte precursors, and then into mature cells. The cells obtained have morphological features and phenotypic markers characteristic of human adult hepatocytes. They also show evidence of cytochrome p450 enzyme activity, validating their utility for commercial applications such as drug screening, or use in the manufacture of medicaments and medical devices for clinical therapy.

Claims (10)

1. A method for screening for a response of cultured hepatocyte lineage cells to an administered chemical compound, the method comprising: a) obtaining a population of cultured cells that are in vitro differentiated progeny of cells expressing SSEA3, SSEA4, TRA-1-60 and TRA-1-81 and have morphological features of hepatocytes; b) administering the chemical compound to the population of cultured cells; and c) measuring a response of the population of cultured cells to the administered compound; wherein the response is selected from a change in the viability, survival, morphology, marker phenotype, metabolic activity, and/or leakage of enzymes into the culture medium of the cultured cells.

2. The method of claim 1 , further comprising: d) obtaining a second population of cultured cells that are in vitro differentiated progeny of cells expressing SSEA3, SSEA4, TRA-1-60 and TRA-1-81 and have morphological features of hepatocytes; wherein the second population of cultured cells are genetically identical to the population of cultured cells of claim 1 , except for a difference at a single polymorphic locus that encodes a drug metabolizing enzyme; e) administering the chemical compound to the second population of cultured cells; and f) measuring a response of the second population of cultured cells to the administered compound; wherein the response is the same response measured in c).

3. The method of claim 2 , wherein the single polymorphic locus is associated with altered toxicity or metabolism.

4. The method of claim 3 , wherein the single polymorphic locus encodes a cytochrome P450 enzyme.

5. The method of claim 1 , wherein the response is a change in the viability of the cultured cells.

6. The method of claim 1 , wherein the response is a change in the survival of the cultured cells.

7. The method of claim 1 , wherein the response is a change in the morphology of the cultured cells.

8. The method of claim 1 , wherein the response is a change in the marker phenotype of the cultured cells.

9. The method of claim 1 , wherein the response is a change in the metabolic activity of the cultured cells.

10. The method of claim 1 , wherein the response is a change in the leakage of enzymes into the culture medium of the cultured cells.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2013
From: GERON CORPORATION
To: ASTERIAS BIOTHERAPEUTICS, INC.
Reel/Frame 031578/0248 →
Continuity (8)
Continuation 12277136 · Nov 24, 2008
Continuation 10810311 · Mar 26, 2004
Continuation In Part 10087142 · Mar 1, 2002
Continuation In Part 10001267 · Oct 31, 2001
Continuation In Part 09872182 · May 31, 2001
Continuation In Part PCTUS0113471 · Apr 26, 2001
Provisional Application 60200095 · Apr 27, 2000
Related Publication 20140106343A1 · Apr 17, 2014